[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338344-105":59,"doc-detail-338344-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","novel-dichloroacetophenone-based-pdhk1-inhibitors-as-potent-anticancer-agents","Novel Dichloroacetophenone-Based PDHK1 Inhibitors as Potent Anticancer Agents","","Pyruvate dehydrogenase kinases (PDHKs) are metabolically important and abnormally expressed in cancer cells, making PDHK1 a promising anticancer target, particularly in non-small-cell lung cancer. A new dichloroacetophenone (DAP) analog, compound 9, was proposed to bind the PDHK1 allosteric pocket using molecular modeling and kinase biochemical assays. Guided by the binding mode and structure-activity relationship (SAR) studies, novel hybrid dichloroacetophenone biphenylsulfone ether analogs were designed, synthesized, and evaluated. Compound 31 and 32 inhibited PDHK1 with low-nanomolar IC50 values, and compound 32 showed acceptable in vitro metabolic stability and favorable ADME/T properties, with promising efficacy in a lung cancer xenograft mouse model.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/novel-dichloroacetophenone-based-pdhk1-inhibitors-as-potent-anticancer-agents/338344/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/novel-dichloroacetophenone-based-pdhk1-inhibitors-as-potent-anticancer-agents/338344.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why target PDHK1 in cancer therapy?","Question",{"text":112,"@type":113},"PDHK1 is a negative regulator of the pyruvate dehydrogenase complex and its abnormal elevation is frequently observed in lung cancer and other solid tumors. Targeting PDHK1 is therefore considered a promising anticancer strategy, especially for non-small-cell lung cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the new DAP analogs designed in this study?",{"text":117,"@type":113},"The work started from a proposed binding mode of DAP analog 9 in the PDHK1 allosteric pocket, guided by molecular modeling. Kinase biochemical experiments and structure–activity relationship (SAR) analysis were then used to design and synthesize new DAP analogs, emphasizing key pocket residues and hydrophobic features.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key in vitro and in vivo findings for compound 32?",{"text":121,"@type":113},"Compound 31 and 32 inhibited PDHK1 with IC50 values of 86 and 140 nM, respectively. Compound 32 additionally showed acceptable in vitro metabolic stability, predicted drug-likeness and ADME/T profiles, and promising therapeutic efficacy in a lung cancer xenograft mouse model.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338344,1790590099,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Drug Design, Development and Therapy Dovepress  \n Open Access Full Text Article ORIGINAL RESEARCH  \nNovel Dichloroacetophenone-Based PDHK1 Inhibitors as Potent Anticancer Agents  \nPuhua Wu 1 , 2 , Zhicheng Zhang 1 , Yan Zhou2 , Quan Liu2 , Kin-Yip Tam2 , Zhenhong Su 1  \n1Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, School of Medicine, Hubei Polytechnic University, Huangshi, People’s Republic of China; 2Cancer Centre, Faculty of Health Sciences, University of Macau, Macau, People’s Republic of China  \nCorrespondence: Puhua Wu, [Email wph75000@hotmail.com](Email wph75000@hotmail.com)  \n\n| Background: Pyruvate dehydrogenase kinases (PDHKs), important metabolic and abnormally expressed enzymes in cancer cells, are promising targets for cancer therapy, especially for non-small-cell lung cancer (NSCLC) .\u003Cbr>Methods: In this study, a new hit, dichloroacetophenone (DAP) analog 9, was postulated to bind to the PDHK1 allosteric pocket, guided by molecular modeling and kinase biochemical experiments. Based on this binding mode, novel DAP analogs were designed and synthesized to confirm the importance of Phe180, Tyr411, and the hydrophobic core at the bottom of the pocket.\u003Cbr>Results: This structure–activity relationship (SAR) study led to the discovery of a novel potent hybrid scaffold, dichloroacetophenone biphenylsulfone ether. Dichloroacetophenone biphenylsulfone ether 31 and 32 inhibited PDHK1 with IC50 values of 86 and 140 nM, respectively.\u003Cbr>Conclusion: Compound 32 with acceptable in vitro metabolic stability, predicted drug-likeness properties and ADME/T profiles, showed promising therapeutic efficacy in a lung cancer xenograft mouse model.\u003Cbr>Keywords: PDHK1, dichloroacetophenone, allosteric pocket, anti-NSCLC activity, tumor xenograft mouse model |\n| --- |\n| Introduction\u003Cbr>Cancer cells predominantly generate ATP through persistent aerobic glycolysis rather than the mitochondrial oxidative phosphorylation (OXPHOS) . This phenomenon is known as the “Warburg effect”.1 The disruption of glucose metabolism in cancer may offer new therapeutic opportunities for cancer treatment.2 The pyruvate dehydrogenase complex (PDC) is a pivotal enzyme in cellular glucose metabolism that links pyruvate to the tricarboxylic acid cycle in mitochondrion.3 Dysfunction of PDC is associated with cancer pathobiology. Pyruvate dehydrogenase kinase (PDHK) is a critical negative regulator of the pyruvate dehydrogenase complex (PDC) . By catalyzing the phosphorylation of serine residues (S300, S293, and S232) in the E1α subunit of PDC, PDHKs can downregulate the activity of PDC.4 Aberrant elevation of PDHKs is frequently observed in lung cancer, pancreatic ductal adenocarcinoma, and other solid cancers.5–8 Four PDHK isoforms have been reported to be involved in cancer progression.8–11 Among these isoforms, PDHK1 is the most closely associated with cancer malignancy, especially non-small-cell lung cancer (NSCLC) .12–15 These results suggest that targeting PDHK1 is a promising strategy for the design of anticancer drugs.\u003Cbr>In the past decade, many small molecular PDHK inhibitors have been reported.16, 17 Representative PDHK inhibitors are shown in Figure 1. Although these representative inhibitors can inactivate PDHKs at nanomolar concentrations, they cannot be used as single agents for the treatment of cancer owing to their low antiproliferative effects on cancer cells. On the other hand, dichloroacetophenones (DAPs) have gradually emerged as a novel class of promising PDHK inhibitors over the past 6 years.18–20 This type of PDHK inhibitor has displayed more potent anticancer activity than other PDHK inhibitors.\u003Cbr>Here, we report the discovery of novel dichloroacetophenones as more potent anti-NSCLC PDHK1 inhibitors than the reported small molecules, guided by molecular modeling and kinase biochemical experiments (Figure 2) . In preliminary SAR exploration, different 4′-alkyloxy/aryloxy substituted DAP derivatives and different li","cbCaifYcGqEwOHLW","https://ap.wps.com/l/cbCaifYcGqEwOHLW","pdf",10711379,"English","# Introduction\n# Results and Discussion\n# Chemistry\n# Conclusions","[{\"question\":\"Why target PDHK1 in cancer therapy?\",\"answer\":\"PDHK1 is a negative regulator of the pyruvate dehydrogenase complex and its abnormal elevation is frequently observed in lung cancer and other solid tumors. Targeting PDHK1 is therefore considered a promising anticancer strategy, especially for non-small-cell lung cancer.\"},{\"question\":\"How were the new DAP analogs designed in this study?\",\"answer\":\"The work started from a proposed binding mode of DAP analog 9 in the PDHK1 allosteric pocket, guided by molecular modeling. Kinase biochemical experiments and structure–activity relationship (SAR) analysis were then used to design and synthesize new DAP analogs, emphasizing key pocket residues and hydrophobic features.\"},{\"question\":\"What were the key in vitro and in vivo findings for compound 32?\",\"answer\":\"Compound 31 and 32 inhibited PDHK1 with IC50 values of 86 and 140 nM, respectively. Compound 32 additionally showed acceptable in vitro metabolic stability, predicted drug-likeness and ADME/T profiles, and promising therapeutic efficacy in a lung cancer xenograft mouse model.\"}]","Novel Dichloroacetophenone-Based PDHK1 Inhibitors as Potent Anticancer Agents | PDF",1790023148,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e82b108f7ea05118b2a638a1f6ea988.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1102dd72b0af9c4a7b8da8fe6e252780.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d10b14b03270bdd17d099bc93b55ea37.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3d702d95d23fb3dfd538ba8e97175dd.webp",980,1268]